Anbio Biotechnology Class A Ordinary Shares (NNNN) Valuation

Valuation

Model-based estimates, not advice. The DCF is the discounted-cash-flow value per share; compare it with the price, not as a target.

DCF fair value

-80.8%

$0.67

vs $3.51 price

Levered DCF

$0.32

After debt service

Piotroski score

3 / 9

Weak

Altman Z-score

1,010.98

Safe zone

Rating

B-

Overall 3 / 5

Ratios by fiscal year

Margins and yields are shares of revenue, equity or price; multiples are ×.

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
P/E	187.94×	103.04×	367.52×	82.9×	227.17×
P/B	43.77×	14.19×	56.03×	66.17×	227.54×
P/S	152.63×	29.81×	123.7×	35.26×	130.29×
EV / EBITDA	227.48×	116.4×	362.16×	82.11×	225.89×
Gross margin	87.2%	71.9%	50.1%	53.4%	57.4%
Operating margin	66.7%	24.4%	29.2%	43.3%	55.5%
Net margin	74.1%	29.0%	33.6%	42.5%	57.3%
Current ratio	344.31×	10.71×	15.86×	9.88×	2.07×
Debt / equity	0×	0×	0×	0×	0×
Interest coverage	0×	0×	0×	1,274.61×	0×
Dividend yield	0.0%	0.0%	0.0%	0.0%	0.0%
Payout ratio	0.0%	0.0%	0.0%	0.0%	0.0%

Key metrics by fiscal year

Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Return on equity	21.2%	13.8%	15.2%	79.8%	100.0%
Return on invested capital	19.1%	11.6%	13.2%	81.3%	96.8%
Return on assets	21.2%	12.5%	14.3%	71.7%	51.6%
Free cash flow yield	-0.5%	0.9%	0.1%	0.5%	0.7%
Earnings yield	0.5%	1.0%	0.3%	1.2%	0.4%
Enterprise value	$1.3B	$232.3M	$820.6M	$823.1M	$572.8M
Net debt / EBITDA	-1.35×	-5.89×	-4.28×	-0.71×	-1.65×
Cash conversion cycle (days)	154	-210	12	-35	-307